ES2991090T3 - Inhibidores de KDM4 - Google Patents
Inhibidores de KDM4 Download PDFInfo
- Publication number
- ES2991090T3 ES2991090T3 ES18774276T ES18774276T ES2991090T3 ES 2991090 T3 ES2991090 T3 ES 2991090T3 ES 18774276 T ES18774276 T ES 18774276T ES 18774276 T ES18774276 T ES 18774276T ES 2991090 T3 ES2991090 T3 ES 2991090T3
- Authority
- ES
- Spain
- Prior art keywords
- kdm4
- cancer
- cells
- compound
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478785P | 2017-03-30 | 2017-03-30 | |
| US201762513875P | 2017-06-01 | 2017-06-01 | |
| PCT/US2018/024624 WO2018183370A2 (en) | 2017-03-30 | 2018-03-27 | Kdm4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2991090T3 true ES2991090T3 (es) | 2024-12-02 |
Family
ID=63678220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18774276T Active ES2991090T3 (es) | 2017-03-30 | 2018-03-27 | Inhibidores de KDM4 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20200039938A1 (https=) |
| EP (1) | EP3600301B1 (https=) |
| JP (1) | JP7442439B2 (https=) |
| ES (1) | ES2991090T3 (https=) |
| TW (1) | TWI814723B (https=) |
| WO (1) | WO2018183370A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR100997A1 (es) * | 2014-06-25 | 2016-11-16 | Quanticel Pharmaceuticals Inc | Derivados de piridina como inhibidores de histona demetilasa |
| US20200039938A1 (en) | 2017-03-30 | 2020-02-06 | Albert-Ludwigs-University Freiburg | Kdm4 inhibitors |
| CN113876953B (zh) * | 2020-07-02 | 2022-12-09 | 中国科学院上海营养与健康研究所 | 新型细胞衰老干预靶点及其在化疗抗癌中的靶向应用 |
| WO2022217100A1 (en) * | 2021-04-09 | 2022-10-13 | Tachyon Therapeutics, Inc. | Treatment of cancer with kdm4 inhibitors |
| CA3227684A1 (en) * | 2021-08-18 | 2023-02-23 | Jr. Richard M. Heid | Process for preparing histone demethylase inhibitors |
| CA3242035A1 (en) * | 2021-12-23 | 2023-06-29 | Gowri Sukumar | Pharmaceutical formulations comprising 3-({[(4r)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4-yl]methyl}amino)pyridine-4-carboxylic acid |
| CN120225189A (zh) * | 2022-09-21 | 2025-06-27 | 细胞基因公司 | 组蛋白去甲基化酶抑制剂3-({[(4r)-7-{甲基[4-(丙烷-2-基)苯基]氨基}-3，4-二氢-2h-1-苯并吡喃-4-基]甲基}氨基)吡啶-4-甲酸l-赖氨酸盐的结晶形式 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| EP1429765A2 (en) | 2001-09-14 | 2004-06-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| GB0307643D0 (en) | 2003-04-02 | 2003-05-07 | Cyclacel Ltd | Markers |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| DE102004039876A1 (de) | 2004-06-23 | 2006-01-26 | Lanxess Deutschland Gmbh | Herstellung von fluorierten 1,3-Benzodioxanen |
| AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| US7898712B2 (en) | 2008-06-27 | 2011-03-01 | Lockheed Martin Corporation | Risley integrated steering module |
| GB201112607D0 (en) | 2011-07-22 | 2011-09-07 | Glaxo Group Ltd | Novel compounds |
| US20140163041A1 (en) * | 2011-02-08 | 2014-06-12 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| EP2701699B1 (en) | 2011-04-28 | 2019-10-16 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| WO2013143597A1 (en) | 2012-03-29 | 2013-10-03 | Glaxo Group Limited | Demethylase enzymes inhibitors |
| WO2014089368A1 (en) | 2012-12-05 | 2014-06-12 | Bio-Rad Laboratories, Inc | Methods for polymerase chain reaction copy number variation assays |
| EP2928471B1 (en) | 2012-12-06 | 2020-10-14 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US8969343B2 (en) | 2012-12-19 | 2015-03-03 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| WO2014100818A1 (en) * | 2012-12-21 | 2014-06-26 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| WO2014139324A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Tetracyclic bromodomain inhibitors |
| EP3290407B1 (en) | 2013-10-18 | 2020-01-01 | Celgene Quanticel Research, Inc | Bromodomain inhibitors |
| US9890434B2 (en) * | 2014-03-19 | 2018-02-13 | National Tsing Hua University | Method for identifying compound for inhibiting an activity of a histone lysine demethylase |
| EP3126345A1 (en) * | 2014-03-31 | 2017-02-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
| SI3137169T1 (sl) | 2014-05-01 | 2022-04-29 | Celgene Quanticel Research, Inc. | Inhibitorji lizin specifične demetilaze-1 |
| AR100997A1 (es) | 2014-06-25 | 2016-11-16 | Quanticel Pharmaceuticals Inc | Derivados de piridina como inhibidores de histona demetilasa |
| EP3397617A4 (en) * | 2015-12-28 | 2019-05-22 | Celgene Quanticel Research, Inc. | HISTONDEMETHYLASEINHIBITOREN |
| US20200039938A1 (en) | 2017-03-30 | 2020-02-06 | Albert-Ludwigs-University Freiburg | Kdm4 inhibitors |
| JP6781095B2 (ja) | 2017-03-31 | 2020-11-04 | エア・ウォーター株式会社 | 化合物半導体基板 |
| WO2019083594A1 (en) | 2017-08-21 | 2019-05-02 | The General Hospital Corporation | COMPOSITIONS AND METHODS FOR CLASSIFYING TUMORS WITH INSTABILITY OF MICROSATELLITES |
| UY38349A (es) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| WO2022217100A1 (en) | 2021-04-09 | 2022-10-13 | Tachyon Therapeutics, Inc. | Treatment of cancer with kdm4 inhibitors |
| CA3227684A1 (en) | 2021-08-18 | 2023-02-23 | Jr. Richard M. Heid | Process for preparing histone demethylase inhibitors |
-
2018
- 2018-03-27 US US16/498,714 patent/US20200039938A1/en not_active Abandoned
- 2018-03-27 US US15/936,811 patent/US20180290977A1/en not_active Abandoned
- 2018-03-27 ES ES18774276T patent/ES2991090T3/es active Active
- 2018-03-27 JP JP2020503253A patent/JP7442439B2/ja active Active
- 2018-03-27 WO PCT/US2018/024624 patent/WO2018183370A2/en not_active Ceased
- 2018-03-27 EP EP18774276.2A patent/EP3600301B1/en active Active
- 2018-03-29 TW TW107110863A patent/TWI814723B/zh active
-
2022
- 2022-05-20 US US17/749,233 patent/US12516024B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7442439B2 (ja) | 2024-03-04 |
| WO2018183370A3 (en) | 2018-12-20 |
| EP3600301A4 (en) | 2020-08-12 |
| WO2018183370A2 (en) | 2018-10-04 |
| TW201840537A (zh) | 2018-11-16 |
| US20180290977A1 (en) | 2018-10-11 |
| EP3600301A2 (en) | 2020-02-05 |
| TWI814723B (zh) | 2023-09-11 |
| EP3600301B1 (en) | 2024-07-03 |
| US20240076271A1 (en) | 2024-03-07 |
| JP2020515645A (ja) | 2020-05-28 |
| US20200039938A1 (en) | 2020-02-06 |
| US12516024B2 (en) | 2026-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2991090T3 (es) | Inhibidores de KDM4 | |
| JP2022017495A (ja) | 癌を治療するための併用療法 | |
| CN107949387B (zh) | 用谷氨酰胺酶抑制剂治疗肺癌 | |
| Wang et al. | Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist | |
| CN111789956B (zh) | 用于抑制化疗引起副作用的药物治疗、筛选技术和试剂盒 | |
| ES2992827T3 (en) | Combination therapies targeting mitochondrial biogenesis for cancer therapy | |
| BR112013028095B1 (pt) | Uso de inibidores de csf-1r para o tratamento de tumores cerebrais | |
| US20100150844A1 (en) | Use of 8-quinolinol and its analogs to target cancer stem cells | |
| KR20240051953A (ko) | Pi3k 이소형 알파를 억제하는 화합물 및 암 치료 방법 | |
| JP2021519302A (ja) | 微小残存がんを治療する方法 | |
| WO2021035048A1 (en) | Use of inhibitors of yap and sox2 for the treatment of cancer | |
| US12377092B2 (en) | Polycomb inhibitors and uses thereof | |
| EP3061451A1 (en) | Kinase inhibitors for the treatment of cancer | |
| US11427543B2 (en) | Compounds for targeting cancer stem cells | |
| CN115607674A (zh) | Rna解旋酶dhx33抑制剂在制备用于治疗胰腺癌的药物中的应用 | |
| KR102882685B1 (ko) | 방사선 치료 민감성 진단용 바이오마커 및 이의 용도 | |
| US20250268898A1 (en) | Methods of treating synovial sarcoma pathogenesis by sumo2 inhibition | |
| Yang | MDM2 Degradation as a Novel and Efficacious Cancer Therapy | |
| Tiwary et al. | Novel peptide targeting CXCR4 disrupt tumor-stroma crosstalk to eliminate migrating cancer stem cells | |
| Tiwary et al. | A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma | |
| JP2024535056A (ja) | 新規の相乗的組合せおよびガンを治療するためのその使用方法 | |
| CN105078983A (zh) | 阿司咪唑、其盐或溶剂合物在制备预防和/或治疗恶性淋巴瘤的药物中的用途 | |
| Ramachandran | Repurposing pimavanserin, an antipsychotic drug for pancreatic cancer and medulloblastoma treatment | |
| Lin et al. | Targeting BMI1 and MCL1 for Lung Adenocarcinoma Treatment | |
| JP2023547108A (ja) | γサブユニットを標的とするミトコンドリアＡＴＰ阻害剤は転移を予防する |